The 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) Trial: a step forward in the treatment of early breast cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72514
Title:
The 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) Trial: a step forward in the treatment of early breast cancer.
Authors:
Howell, Anthony ( 0000-0002-3879-5991 )
Abstract:
The ATAC trial is the first study to compare a third-generation aromatase inhibitor (AI), anastrozole, with tamoxifen for the adjuvant treatment of early breast cancer. Analyses at 33 and 47 months of median follow-up showed that anastrozole significantly prolonged disease-free survival (DFS) and time to recurrence (TTR), and reduced the incidence of contralateral breast cancer, compared with tamoxifen. Results of the Completed Treatment Analysis at 68 months of median follow-up confirmed the superiority of anastrozole over tamoxifen. The absolute difference in DFS between anastrozole and tamoxifen continued to increase beyond completion of treatment and early improvements in DFS and TTR have translated into a benefit in time to distant recurrence. Benefits of anastrozole over tamoxifen were maintained without a detrimental impact on quality of life. Mature safety data with extensive patient exposure indicate that overall, anastrozole has a favourable safety profile compared with tamoxifen. Importantly, a decrease in the odds ratio of cardiovascular events was observed with anastrozole compared with tamoxifen. The ATAC trial provides the most mature data of any AI trial and has enabled the evaluation of a full risk:benefit profile of anastrozole.
Affiliation:
CRUK Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. Howell@christie-tr.nwest.nhs.uk
Citation:
The 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) Trial: a step forward in the treatment of early breast cancer. 2006, 1 (3):207-15 Rev Recent Clin Trials
Journal:
Reviews on Recent Clinical Trials
Issue Date:
Sep-2006
URI:
http://hdl.handle.net/10541/72514
PubMed ID:
18473974
Type:
Article
Language:
en
ISSN:
1574-8871
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Anthony-
dc.date.accessioned2009-07-06T08:32:33Z-
dc.date.available2009-07-06T08:32:33Z-
dc.date.issued2006-09-
dc.identifier.citationThe 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) Trial: a step forward in the treatment of early breast cancer. 2006, 1 (3):207-15 Rev Recent Clin Trialsen
dc.identifier.issn1574-8871-
dc.identifier.pmid18473974-
dc.identifier.urihttp://hdl.handle.net/10541/72514-
dc.description.abstractThe ATAC trial is the first study to compare a third-generation aromatase inhibitor (AI), anastrozole, with tamoxifen for the adjuvant treatment of early breast cancer. Analyses at 33 and 47 months of median follow-up showed that anastrozole significantly prolonged disease-free survival (DFS) and time to recurrence (TTR), and reduced the incidence of contralateral breast cancer, compared with tamoxifen. Results of the Completed Treatment Analysis at 68 months of median follow-up confirmed the superiority of anastrozole over tamoxifen. The absolute difference in DFS between anastrozole and tamoxifen continued to increase beyond completion of treatment and early improvements in DFS and TTR have translated into a benefit in time to distant recurrence. Benefits of anastrozole over tamoxifen were maintained without a detrimental impact on quality of life. Mature safety data with extensive patient exposure indicate that overall, anastrozole has a favourable safety profile compared with tamoxifen. Importantly, a decrease in the odds ratio of cardiovascular events was observed with anastrozole compared with tamoxifen. The ATAC trial provides the most mature data of any AI trial and has enabled the evaluation of a full risk:benefit profile of anastrozole.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Recurrenceen
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshBreast Neoplasms-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshNeoplasm Recurrence, Local-
dc.subject.meshQuality of Life-
dc.subject.meshTamoxifen-
dc.subject.meshTreatment Outcome-
dc.titleThe 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) Trial: a step forward in the treatment of early breast cancer.en
dc.typeArticleen
dc.contributor.departmentCRUK Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. Howell@christie-tr.nwest.nhs.uken
dc.identifier.journalReviews on Recent Clinical Trialsen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.